Clinical Trial Update: Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alemtuzumab in combination with cyclosporine for preventing graft-versus-host disease after stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Graft Versus Host Disease, Bone Marrow Transplantation | Phase 2 | Status: COMPLETED